Active Biotech AB Interim report January - June 2015
(Thomson Reuters ONE) -
· Operations focused on the laquinimod projects and organization adjusted
accordingly
Laquinimod
· The pivotal CONCERTO clinical Phase III study in relapsing remitting MS (RRMS)
is fully enrolled and results are expected in 2017
· The first patient was enrolled for the ARPEGGIO Phase II study, which will
evaluate laquinimod's potential for treatment of primary progressive multiple
sclerosis (PPMS)
· The Phase II study LEGATO-HD into Huntington's disease is proceeding according
to plan
· Laquinimod presented by Teva at the AAN Annual Meeting on April 18-25, 2015
Tasquinimod
· Results from the Phase III study 10TASQ10 showed that treatment with
tasquinimod significantly reduced the risk of radiographic cancer progression
compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with
metastatic castration-resistant prostate cancer (mCRPC) who have not received
chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 -
1.28).
· Further development of tasquinimod discontinued and the collaboration
agreement with Ipsen terminated
ISI
· Only commercial activities will be conducted from 2016
Financial summary
MSEK April - June Jan. - June Jan. - Dec.
2015 2014 2015 2014 2014
------------------------------------------------------------------------
Net sales 3.2 2.7 6.1 4.9 10.4
Operating loss -70.1 -57.9 -127.5 -117.2 -228.5
Loss for the period -71.4 -57.7 -129.3 -117.9 -231.5
Loss per share (SEK) -0.79 -0.77 -1.44 -1.57 -3.02
Cash and cash equivalents 186.6 227.7 328.5
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
The report is also available at www.activebiotech.com
Active Biotech AB
Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
Active Biotech AB Interim report January - June 2015:
http://hugin.info/1002/R/1944149/704251.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
[HUG#1944149]
Unternehmensinformation / Kurzprofil:
Datum: 07.08.2015 - 08:31 Uhr
Sprache: Deutsch
News-ID 412287
Anzahl Zeichen: 3121
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 142 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - June 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
